ZA200408342B - Tricyclic thrombin receptor antagonists - Google Patents

Tricyclic thrombin receptor antagonists

Info

Publication number: ZA200408342B
Authority: ZA; South Africa
Prior art keywords: receptor antagonists; thrombin receptor; tricyclic thrombin; tricyclic; antagonists
Prior art date: 2002-04-16

Application number

ZA200408342A

Other languages

English (en)

Inventor

Samuel Chackalamannil

William J Greenlee

Yan Xia

Mariappan Chelliah

Martin C Clasby

Yuguang Wang

Enrico P Veltri

Wenxue Wu

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-16

Filing date

2004-10-14

Publication date

2006-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200408342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-14 Application filed by Schering Corp filed Critical Schering Corp

2006-05-31 Publication of ZA200408342B publication Critical patent/ZA200408342B/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200408342A 2002-04-16 2004-10-14 Tricyclic thrombin receptor antagonists ZA200408342B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37307202P	2002-04-16	2002-04-16

Publications (1)

Publication Number	Publication Date
ZA200408342B true ZA200408342B (en)	2006-05-31

Family

ID=29250954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200408342A ZA200408342B (en)	2002-04-16	2004-10-14	Tricyclic thrombin receptor antagonists

Country Status (34)

Country	Link
US (3)	US7304078B2 (xx)
EP (5)	EP2062890B1 (xx)
JP (2)	JP4558331B2 (xx)
KR (1)	KR101026929B1 (xx)
CN (1)	CN1659162B (xx)
AR (1)	AR039570A1 (xx)
AT (3)	ATE378330T1 (xx)
AU (1)	AU2003221932B2 (xx)
BR (1)	BRPI0309309B8 (xx)
CA (1)	CA2482858C (xx)
CY (3)	CY1107184T1 (xx)
DE (3)	DE60317493T3 (xx)
DK (2)	DK2065384T3 (xx)
EC (1)	ECSP045368A (xx)
ES (3)	ES2357876T3 (xx)
FR (1)	FR15C0047I2 (xx)
HK (3)	HK1070887A1 (xx)
IL (1)	IL164585A (xx)
LT (1)	LTC1495018I2 (xx)
LU (1)	LU92759I2 (xx)
MX (1)	MXPA04010308A (xx)
MY (1)	MY144040A (xx)
NL (1)	NL300746I1 (xx)
NO (2)	NO330500B1 (xx)
NZ (2)	NZ575139A (xx)
PE (1)	PE20040412A1 (xx)
PL (1)	PL214718B1 (xx)
PT (2)	PT1495018E (xx)
RU (2)	RU2329264C9 (xx)
SG (1)	SG164279A1 (xx)
SI (2)	SI1495018T1 (xx)
TW (1)	TWI343919B (xx)
WO (1)	WO2003089428A1 (xx)
ZA (1)	ZA200408342B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CA2567981C (en) *	2004-05-28	2010-08-31	Schering Corporation	Constrained himbacine analogs as thrombin receptor antagonists
JP2008515908A (ja) *	2004-10-06	2008-05-15	ユニバーシティーオブロチェスター	組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療
PT1848705E (pt) *	2005-01-14	2010-05-10	Schering Corp	Sínteses exo- e diastereo-selectivas de análogos da himbacina
US7541471B2 (en) *	2005-01-14	2009-06-02	Schering Corporation	Synthesis of himbacine analogs
WO2006076565A2 (en) *	2005-01-14	2006-07-20	Schering Corporation	Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
EP1853592B1 (en) *	2005-01-14	2011-03-02	Schering Corporation	Synthesis of himbacine analogs
US7772276B2 (en)	2005-01-14	2010-08-10	Schering Corporation	Exo-selective synthesis of himbacine analogs
WO2006105217A2 (en)	2005-03-31	2006-10-05	Schering Corporation	Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) *	2005-12-20	2007-09-20	Suxing Liu	Methods for preventing and/or treating a cell proliferative disorder
CN101384259A (zh) *	2005-12-22	2009-03-11	先灵公司	作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
PE20080183A1 (es) *	2006-04-06	2008-03-10	Schering Corp	Terapias de combinacion de tra
EP2007755B1 (en) *	2006-04-13	2012-06-27	Schering Corporation	Fused ring thrombin receptor antagonists
AR061664A1 (es) *	2006-06-29	2008-09-10	Schering Corp	Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
AR061727A1 (es) *	2006-06-30	2008-09-17	Schering Corp	Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en)	2006-06-30	2012-07-01	Schering Corp	Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de)	2006-08-02	2008-02-07	Sanofi-Aventis	Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) *	2006-09-26	2011-06-11	Schering Corp	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
JP2010505842A (ja)	2006-10-04	2010-02-25	シェーリングコーポレイション	トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
WO2008060372A2 (en) *	2006-10-04	2008-05-22	Schering Corporation	Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
EP2120879A2 (en) *	2006-12-22	2009-11-25	Schering Corporation	Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) *	2007-03-23	2014-09-09	Schering Corp	Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
PT2240487E (pt)	2008-02-05	2012-03-08	Sanofi Sa	Triazolopiridazinas como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
RU2494100C2 (ru)	2008-02-05	2013-09-27	Санофи-Авентис	Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства
WO2009124103A2 (en) *	2008-04-02	2009-10-08	Schering Corporation	Combination therapies comprising par1 antagonists with par4 antagonists
EP2805939B1 (en)	2008-05-19	2018-06-27	Merck Sharp & Dohme Corp.	Heterocyclic compounds as factor IXA inhibitors.
PL2438060T3 (pl)	2009-06-04	2014-03-31	Merck Sharp & Dohme	Aktywny metabolit antagonisty receptora trombiny
WO2010144339A2 (en)	2009-06-08	2010-12-16	Schering Corporation	A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (en)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
ES2527535T3 (es)	2010-04-16	2015-01-26	Sanofi	Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
ES2532902T3 (es)	2010-04-16	2015-04-01	Sanofi	Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1
KR101303348B1 (ko)	2010-06-25	2013-09-03	한국화학연구원	트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en)	2012-03-06	2016-05-17	Merck Sharp & Dohme Corp.	Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015013083A1 (en) *	2013-07-22	2015-01-29	Merck Sharp & Dohme Corp.	Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
WO2015026693A1 (en) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US20160200715A1 (en)	2013-08-22	2016-07-14	Merck Sharp & Dohme Corp.	Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
EP3035928B1 (en)	2013-08-22	2023-10-18	Merck Sharp & Dohme LLC	3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr)	2013-12-16	2016-01-08	Pf Medicament	Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EP3131897B8 (en)	2014-04-16	2022-08-03	Merck Sharp & Dohme LLC	Factor ixa inhibitors
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
CN105985303B (zh) *	2015-02-13	2020-08-14	上海彩迩文生化科技有限公司	抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) *	2015-09-01	2017-03-08	博瑞生物医药（苏州）股份有限公司	沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) *	2015-11-25	2017-05-31	博瑞生物医药（苏州）股份有限公司	一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) *	2016-02-05	2018-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) *	2016-02-05	2017-08-10	Sanovel Ilac Sanayi Ve Ticaret A.S.	A novel pharmaceutical composition of vorapaxar and metoprolol
CN107304200B (zh) *	2016-04-22	2021-09-21	江苏天士力帝益药业有限公司	一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) *	2016-08-22	2016-12-21	孔五	一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr)	2018-12-19	2021-05-07	Cvasthera	Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) *	2019-08-02	2020-06-26	牡丹江医学院	一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) *	2019-10-21	2021-04-22	United States Government as Represented by the Department of Veteran Affairs	Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr)	2020-04-08	2023-04-14	Cvasthera	Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660A (zh)	2020-07-22	2023-05-16	詹森药业有限公司	可用作因子XIa抑制剂的化合物
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr)	2022-04-08	2023-10-13	Cvasthera	Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2623810B2 (fr)	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en)	1992-07-30	1999-11-30	Cor Therapeutics Inc	Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en)	1994-01-31	1996-11-19	Elf Sanofi	Method for the secondary prevention of ischemic events
ZA9810685B (en) *	1997-11-25	1999-12-23	Schering Corp	Thrombin receptor antagonists.
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
FR2779726B1 (fr)	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
US6645987B2 (en) *	2000-06-15	2003-11-11	Schering Corporation	Nor-seco himbacine derivatives useful as thrombin receptor antagonists
MY139335A (en)	2001-10-18	2009-09-30	Schering Corp	Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

2003
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko active IP Right Grant
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en active Application Filing
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
2004
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
2005
- 2005-04-22 HK HK05103479A patent/HK1070887A1/xx not_active IP Right Cessation
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
2009
- 2009-03-23 HK HK09102736.6A patent/HK1123302A1/xx not_active IP Right Cessation
- 2009-09-14 HK HK09108388.4A patent/HK1129893A1/xx not_active IP Right Cessation
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
2015
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-06-29 NL NL300746C patent/NL300746I1/nl unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I1/el unknown

Also Published As

Publication number	Publication date
BRPI0309309B1 (pt)	2018-09-04
BR0309309A (pt)	2005-02-15
NL300746I2 (xx)	2016-01-21
EP1495018B3 (en)	2011-03-16
CY1111363T1 (el)	2015-08-05
EP1495018A1 (en)	2005-01-12
RU2008106401A (ru)	2009-08-27
CN1659162A (zh)	2005-08-24
ATE378330T1 (de)	2007-11-15
US7304078B2 (en)	2007-12-04
DE60317493D1 (en)	2011-01-13
EP1860106A1 (en)	2007-11-28
TW200404068A (en)	2004-03-16
CN1659162B (zh)	2011-08-31
CY2015029I2 (el)	2016-04-13
US20030216437A1 (en)	2003-11-20
KR20040099441A (ko)	2004-11-26
PE20040412A1 (es)	2004-07-12
DE60317493T2 (de)	2008-09-18
PT1495018E (pt)	2008-02-19
HK1129893A1 (en)	2009-12-11
AU2003221932A1 (en)	2003-11-03
FR15C0047I1 (xx)	2015-08-28
US20070179187A1 (en)	2007-08-02
EP1982984B1 (en)	2013-02-13
NZ535880A (en)	2007-11-30
HK1123302A1 (en)	2009-06-12
DE60335679D1 (de)	2011-02-17
CA2482858A1 (en)	2003-10-30
TWI343919B (en)	2011-06-21
EP1982984A3 (en)	2008-10-29
ECSP045368A (es)	2005-01-03
CY2015029I1 (el)	2016-04-13
NO20044963L (no)	2004-11-15
EP2065384B1 (en)	2011-01-05
EP1982984A2 (en)	2008-10-22
ES2297150T7 (es)	2012-03-16
NO2015016I2 (no)	2015-07-09
EP1495018B1 (en)	2007-11-14
CA2482858C (en)	2010-11-30
CY1107184T1 (el)	2012-10-24
EP2062890B1 (en)	2011-01-05
JP2005528406A (ja)	2005-09-22
IL164585A (en)	2010-11-30
AU2003221932B2 (en)	2007-11-22
DK1495018T3 (da)	2008-02-18
PL214718B1 (pl)	2013-09-30
ES2357876T3 (es)	2011-05-03
PT2065384E (pt)	2011-03-16
US20070270439A1 (en)	2007-11-22
JP4558331B2 (ja)	2010-10-06
EP1860106B1 (en)	2010-01-20
NO2015016I1 (no)	2015-07-20
ES2297150T3 (es)	2008-05-01
NL300746I1 (xx)	2016-01-21
MXPA04010308A (es)	2005-02-03
LU92759I2 (en)	2015-08-31
DE60317493T3 (de)	2018-07-12
AR039570A1 (es)	2005-02-23
ATE455774T1 (de)	2010-02-15
JP2010132710A (ja)	2010-06-17
ATE494284T1 (de)	2011-01-15
BRPI0309309B8 (pt)	2021-05-25
KR101026929B1 (ko)	2011-04-04
SI1495018T1 (sl)	2008-04-30
MY144040A (en)	2011-07-29
DK2065384T3 (da)	2011-05-02
SG164279A1 (en)	2010-09-29
EP2065384A1 (en)	2009-06-03
RU2004133375A (ru)	2005-07-10
RU2329264C9 (ru)	2009-04-20
NZ575139A (en)	2010-08-27
LTC1495018I2 (lt)	2017-04-10
PL373332A1 (en)	2005-08-22
US7713999B2 (en)	2010-05-11
FR15C0047I2 (fr)	2016-05-06
HK1070887A1 (en)	2005-06-30
SI2065384T1 (sl)	2011-05-31
WO2003089428A1 (en)	2003-10-30
NO330500B1 (no)	2011-05-02
RU2329264C2 (ru)	2008-07-20
IL164585A0 (en)	2005-12-18
EP2062890A1 (en)	2009-05-27
DE60331114D1 (de)	2010-03-11
ES2338171T3 (es)	2010-05-04

Publication	Publication Date	Title
HK1070887A1 (en)	2005-06-30	Tricyclic thrombin receptor antagonists
IL174538A0 (en)	2006-08-01	Thrombin receptor antagonists
AU2003261392A8 (en)	2004-02-23	M3muscarinic acetylcholine receptor antagonists
HK1090922A1 (en)	2007-01-05	Cgrp receptor antagonists cgrp
AU6690001A (en)	2001-12-24	Thrombin receptor antagonists
ZA200702790B (en)	2008-09-25	Thrombin receptor antagonists
EP1641781A4 (en)	2010-06-23	BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS
IL172822A0 (en)	2006-06-11	Muscarnic acetylcholine receptor antagonists
IL165841A0 (en)	2006-01-15	Mchir antagonists
PL378753A1 (pl)	2006-05-15	Antagoniści receptora CCR-3
AU2003291959A8 (en)	2004-07-14	Novel glucagon antagonists
IL165727A0 (en)	2006-01-15	Chemokine antagonists
AU2003240705A1 (en)	2003-12-02	Morpholinylmethylureas ccr-3 receptor antagonists
AU2003297773A8 (en)	2004-07-29	Heteroaryl peptidomimetics as thrombin receptor antagonists
EP1696949A4 (en)	2008-02-06	VEGF Receptor Antagonists
AU2003287219A8 (en)	2004-05-25	Il-8 receptor antagonists
IL162534A0 (en)	2005-11-20	Novel alkansulfonamides as endotheline antagonists
GB0302094D0 (en)	2003-02-26	EP4 receptor antagonists
GB0026327D0 (en)	2000-12-13	Thrombin receptor antagonists
EP1534736A4 (en)	2006-11-02	NOGO RECEPTOR ANTAGONISTS
SI1294714T1 (sl)	2007-12-31	Antagonisti trobinskega receptorja
GB0317346D0 (en)	2003-08-27	5-ht2b receptor antagonists